C&R Research pitches Korea as a faster hub for global clinical trials

South Korea is drawing attention as a lower-cost, faster site for multinational clinical trials, and C&R Research is positioning itself as the local partner to navigate the market. The CRO points to strong patient recruitment, faster start-up timelines and global regulatory experience as demand for Korea grows.

Why it matters: - South Korea is emerging as a practical answer to two persistent problems in global clinical trials: high cost and slow patient recruitment. - The market’s value comes from its combination of broad insurance coverage, dense trial infrastructure and fast start-up timelines. - C&R Research is using that backdrop to sell itself as the local operator that can turn Korea’s advantages into faster development paths for sponsors.

What happened: - C&R Research said Korea is gaining traction as a hub for multi-regional clinical trials because of strong recruitment conditions and advanced medical infrastructure. - The company said Korea’s national health insurance system covers 99.6% of the population. - The company said more than 200 clinical trial institutions designated by the Ministry of Food and Drug Safety support recruitment speed. - C&R Research said trial start-up can be completed in about 4.5 to 5 months. - The company said zero Official Action Indicated classifications in U.S. FDA inspections reflect strong regulatory compliance and data integrity.

The details: - C&R Research said it has spent 29 years building Korea’s largest CRO track record. - The company said it has conducted more than 2,800 clinical trials. - C&R Research said its network with top-tier Korean trial sites helps move work from protocol planning to patient enrollment faster. - The company said it received the highest-ever score in the Korea National Enterprise for Clinical Trials Innovative CRO evaluation. - C&R Research said it has led multinational clinical trials across more than 25 countries, including the U.S., Singapore, Thailand and Indonesia. - The company said its regulatory affairs team works with FDA and EMA requirements and builds strategies for specific development needs. - Global inbound contracts in 2025 reached 2.6 times the 2023 level, according to the company. - C&R Research said it has integrated an AI-powered eClinical platform to speed drug development and improve trial success rates. - The company identified itself as Korea’s first CRO and said it has built the country’s only end-to-end model across the drug development journey. - Contact information in the release listed Jisung Myeong, Brand Marketing Specialist at C&R Research Inc., at PR@cnrres.com. - The release also directed readers to more information.

Between the lines: - Korea is being framed as more than a low-cost alternative; the pitch is that the country can also reduce operational friction that often slows global studies. - C&R Research is positioning its local history, regulatory knowledge and international footprint as the differentiator that makes Korea easier to use for overseas sponsors. - The emphasis on AI and eClinical tools suggests the company wants to be seen as both a traditional CRO and a technology-enabled trial partner.

What’s next: - C&R Research is likely to keep targeting multinational sponsors that want faster enrollment and shorter start-up timelines in Asia. - The company’s global contract growth suggests it will continue leaning on its international network and regulatory team to win inbound work. - Further adoption of AI-enabled clinical tools could become a bigger part of the company’s pitch as competition for trial locations intensifies.

The bottom line: - Korea’s clinical trial appeal is rising, and C&R Research wants to be the local gatekeeper that makes that advantage usable for global drug developers.